Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.65 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577619 | 0.87 | TRPV1 (0.69) | TRPV1NAMPTMAPK14ROCK2ROCK1 | |
| SCHEMBL3386390 | 0.82 | NAMPT (0.59) | TRPV1NAMPTMAPK14ROCK2ROCK1 | |
| SCHEMBL3576445 | 0.81 | NAMPT (0.68) | TRPV1NAMPTMAPK14ROCK2ROCK1 | |
| SCHEMBL3387196 | 0.79 | BCHE (0.49) | CNR1RAF1 | |
| SCHEMBL27422506 | 0.78 | CNR1 (0.67) | TRPV1NAMPTMAPK14ROCK2ROCK1 | |
| SCHEMBL7643257 | 0.78 | CNR1 (0.63) | TRPV1NAMPTMAPK14ROCK2ROCK1 | |
| SCHEMBL7880446 | 0.78 | TRPV1 (0.73) | TRPV1RAB9A | |
| SCHEMBL14266549 | 0.77 | TRPV1 (0.59) | TRPV1NAMPTMAPK14ROCK2ROCK1 | |
| SCHEMBL5563990 | 0.76 | CNR1 (0.53) | TRPV1NAMPTMAPK14ROCK2ROCK1 | |
| SCHEMBL6989302 | 0.76 | CNR1 (0.58) | TRPV1MAPK14ROCK2ROCK1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984002-B1 | TRIALKYLSILYLBENZYLAMINOCARBOXYINDOLES, INDAZOLES AND INDOLINES AND THEIR USE IN TREATING CETP-MEDIATED DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-7572823-B2 | Heteroaryl carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1984002-A1 | TRIALKYLSILYLBENZYLAMINOCARBOXYINDOLES, INDAZOLES AND INDOLINES AND THEIR USE IN TREATING CETP-MEDIATED DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090750-A1 | TRIALKYLSILYLBENZYLAMINOCARBOXYINDOLES, INDAZOLES AND INDOLINES AND THEIR USE IN TREATING CETP-MEDIATED DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185182-A1 | Heteroaryl carboxamide compounds | HOFFMAN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185182-A1 | Heteroaryl carboxamide compounds | ABCB1, ABCG2, CYP3A43 | TRPV1 228/4885NAMPT 742/4885MAPK14 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.